CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionPrice-to-book is 35.71×, higher than 95% of its Biotechnology peers (median 2.97×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
603.40MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.2470xvs all stocks
52-Week Change
139.85%vs all stocks
Market Capitalization
603.40MUSDvs all stocks (USD)
Enterprise Value
468.24MUSDvs all stocks (USD)
Forward P/E
-19.94xvs Biotechnology peers
Price to Book (MRQ)
35.71xvs Biotechnology peers
Enterprise to EBITDA
-16.98xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-63.61%vs Biotechnology peers
Return on Equity (TTM)
-154.43%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-29.59MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-18.35MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.17MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-27.57MUSDvs all stocks (USD)
Pre-tax Income
-26.44MUSDFY2025 · Dec 31, 2025Net Income
-26.44MUSDFY2025 · Dec 31, 2025EBIT
-27.57MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-27.57MUSDFY2025 · Dec 31, 2025Research & Development
18.15MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
9.42MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.13MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-26.44MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
2.43MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-15.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
31.63MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-26.44MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.78MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.35MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.11MUSDFY2025 · Dec 31, 2025Shares Outstanding
26.53MSharesUpdated Jul 19, 2026Float Shares
16.98MSharesUpdated Jul 19, 2026Shares Short
1.80MSharesUpdated Jul 19, 2026Short Ratio
4.18daysvs all stocks
Short % of Shares Outstanding
11.56%vs all stocks
% Held by Insiders
35.49%vs all stocks
% Held by Institutions
14.43%vs all stocks
Total Cash (MRQ)
25.13MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9470USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
2.27xvs Biotechnology peers
Book Value per Share (MRQ)
0.5360USDUpdated Jul 19, 2026Total Assets
31.71MUSDvs all stocks (USD)
Total Current Assets
31.71MUSDFY2025 · Dec 31, 2025Total Liabilities
13.30MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
13.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
31.63MUSDFY2025 · Dec 31, 2025Accounts Payable
6.27MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-99.69MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
18.41MUSDvs all stocks (USD)
52-Week Low
5.55USDUpdated Jul 19, 202652-Week High
29.27USDUpdated Jul 19, 202652-Week Change
139.85%vs all stocks
Beta
-0.2470xvs all stocks
50-Day MA
14.19USDUpdated Jul 19, 2026200-Day MA
9.27USDUpdated Jul 19, 2026Avg 10-Day Volume
275.40KSharesUpdated Jul 19, 2026Avg 30-Day Volume
437.11KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.31USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 35.71×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 35.71Industry median: 2.97Industry P95: 23.50Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Bohui Innovation Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Xiao Feng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
FDC Ltd.
Tier 1ProductionApproval-Gated PipelineRule